Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
{{output}}
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender w... ...
